| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2016 | ARMAGEN INC. | 26679 AGOURA RD STE 100 | CALABASAS | CA | 91302-3811 | LOS ANGELES | USA | R44NS088868 | Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome | 000 | 3 | NIH | 4/18/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $612,428 ) |
| | 2016 | 2016 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44NS088868 | Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome | 000 | 3 | NIH | 4/7/2016 | $612,428 |
|
| Issue Date FY: 2015 ( Subtotal = $421,005 ) |
| | 2015 | 2015 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44NS088868 | Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome | 000 | 2 | NIH | 3/11/2015 | $421,005 |
|
| Issue Date FY: 2014 ( Subtotal = $1,325,016 ) |
| | 2014 | 2014 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44HD074272 | Metachromatic Leukodystrophy Enzyme Drug Development | 000 | 3 | NIH | 4/4/2014 | $583,336 |
| | 2014 | 2014 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44AG042181 | Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein | 000 | 3 | NIH | 2/21/2014 | $589,542 |
| | 2014 | 2014 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R43NS088868 | Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome | 000 | 1 | NIH | 5/6/2014 | $152,138 |
|
| Issue Date FY: 2013 ( Subtotal = $1,454,138 ) |
| | 2013 | 2013 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44AG042181 | Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein | 000 | 2 | NIH | 2/27/2013 | $391,592 |
| | 2013 | 2013 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44HD074272 | Metachromatic Leukodystrophy Enzyme Drug Development | 000 | 2 | NIH | 3/29/2013 | $416,309 |
| | 2013 | 2013 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44NS067707 | ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II | 000 | 3 | NIH | 12/19/2012 | $646,237 |
|
| Issue Date FY: 2012 ( Subtotal = $1,219,426 ) |
| | 2012 | 2012 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R43HD074272 | METACHROMATIC LEUKODYSTROPHY ENZYME DRUG DEVELOPMENT | 000 | 1 | NIH | 7/31/2012 | $156,555 |
| | 2012 | 2012 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R43HD074272 | METACHROMATIC LEUKODYSTROPHY ENZYME DRUG DEVELOPMENT | 001 | 1 | NIH | 8/2/2012 | $0 |
| | 2012 | 2012 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R43AG042181 | MANUFACTURING OF TROJAN HORSE-TNFR DECOY RECEPTOR FUSION PROTEIN | 000 | 1 | NIH | 3/8/2012 | $148,530 |
| | 2012 | 2012 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44NS067707 | ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II | 000 | 2 | NIH | 11/17/2011 | $406,198 |
| | 2012 | 2012 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44MH083334 | BIOENGINEERING OF A NEW ANTIBODY DRUG DELIVERY TECHNOLOGY | 000 | 3 | NIH | 3/29/2012 | $508,143 |
|
| Issue Date FY: 2011 ( Subtotal = $1,573,699 ) |
| | 2011 | 2011 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R44MH083334 | BIOENGINEERING OF A NEW ANTIBODY DRUG DELIVERY TECHNOLOGY | 000 | 2 | NIH | 3/23/2011 | $334,803 |
| | 2011 | 2011 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R43NS074539 | RE-ENGINEERING BLOOD-BORNE ERYTHROPOIETIN FOR TARGETED DELIVERY | 000 | 1 | NIH | 3/2/2011 | $149,800 |
| | 2011 | 2011 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R43NS067707 | ENZYME REPLACEMENT THERAPY OF THE BRAIN IN MUCOPOLYSACCHARIDOSIS TYPE II | 000 | 1 | NIH | 1/17/2011 | $111,214 |
| | 2011 | 2011 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | U44NS064602 | IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME | 000 | 3 | NIH | 6/6/2011 | $898,274 |
| | 2011 | 2011 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | U44NS064602 | IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME | 001 | 3 | NIH | 6/10/2011 | $79,608 |
|
| Issue Date FY: 2010 ( Subtotal = $982,874 ) |
| | 2010 | 2010 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | U44NS064602 | IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME | 000 | 2 | NIH | 6/29/2010 | $982,874 |
| | 2010 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R44NS044654 | NEUROPROTECTION IN STROKE DRUG DEVELOPMENT | 000 | 7 | NIH | 6/15/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $1,964,946 ) |
| | 2009 | 2009 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | U44NS064602 | IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME | 000 | 1 | NIH | 6/5/2009 | $980,092 |
| | 2009 | 2009 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R43NS062458 | TARGETED DELIVERY OF SIRNA FOR INTRAVENOUS RNAI | 000 | 2 | NIH | 8/20/2009 | $195,742 |
| | 2009 | 2009 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | R43NS066514 | BIOENGINEERING OF A NEW DECOY RECEPTOR DRUG DELIVERY TECHNOLOGY | 000 | 1 | NIH | 8/20/2009 | $111,999 |
| | 2009 | 2009 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401-2717 | | USA | U44NS057843 | TARGETED PARAOXONASE FUSION PROTEIN AS A NEUROTHERAPEUTIC FOR NERVE GAS AGENTS | 000 | 4 | NIH | 7/22/2009 | $677,113 |
| | 2009 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R44NS044654 | NEUROPROTECTION IN STROKE DRUG DEVELOPMENT | 000 | 7 | NIH | 11/3/2008 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $2,467,858 ) |
| | 2008 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R43HD057631 | IDURONIDASE REPLACEMENT THERAPY OF THE BRAIN IN HURLER'S SYNDROME | 000 | 1 | NIH | 2/6/2008 | $100,000 |
| | 2008 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R43NS062458 | TARGETED DELIVERY OF SIRNA FOR INTRAVENOUS RNAI | 000 | 1 | NIH | 9/11/2008 | $190,038 |
| | 2008 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R43NS060176 | TARGETED NEUROTROPHIN DRUG DEVELOPMENT IN PARKINSON'S DISEASE | 000 | 1 | NIH | 3/21/2008 | $100,000 |
| | 2008 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R44HD052303 | RECOMBINANT ENZYME FUSION PROTEIN FOR LYSOSOMAL STORAGE DISORDERS | 000 | 3 | NIH | 3/4/2008 | $456,597 |
| | 2008 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R44NS044654 | NEUROPROTECTION IN STROKE DRUG DEVELOPMENT | 000 | 7 | NIH | 8/28/2008 | $977,098 |
| | 2008 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | U44NS057843 | TARGETED PARAOXONASE FUSION PROTEIN AS A NEUROTHERAPEUTIC FOR NERVE GAS AGENTS | 000 | 3 | NIH | 6/4/2008 | $495,075 |
| | 2008 | 2008 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R43MH083334 | BIOENGINEERING OF A NEW ANTIBODY DRUG DELIVERY TECHNOLOGY | 000 | 1 | NIH | 9/15/2008 | $149,050 |
|
| Issue Date FY: 2007 ( Subtotal = $2,189,562 ) |
| | 2007 | 2007 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R44NS051076 | STROKE NEUROPROTECTION WITH A RECOMBINANT FUSION PROTEIN | 000 | 3 | NIH | 7/18/2007 | $374,421 |
| | 2007 | 2007 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R44NS044654 | NEUROPROTECTION IN STROKE DRUG DEVELOPMENT | 000 | 6 | NIH | 9/25/2007 | $977,098 |
| | 2007 | 2007 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | U44NS057843 | TARGETED PARAOXONASE FUSION PROTEIN AS A NEUROTHERAPEUTIC FOR NERVE GAS AGENTS | 000 | 2 | NIH | 7/20/2007 | $480,657 |
| | 2007 | 2007 | ARMAGEN TECHNOLOGIES INC | 914 COLORADO BOULEVARD | LOS ANGELES | CA | 90401 | | USA | R44HD052303 | RECOMBINANT ENZYME FUSION PROTEIN FOR LYSOSOMAL STORAGE DISORDERS | 000 | 2 | NIH | 4/19/2007 | $357,386 |
|
| Issue Date FY: 2006 ( Subtotal = $2,150,507 ) (Continued on the next page) |
| | 2006 | 2006 | ARMAGEN TECHNOLOGIES INC | 11301 OLYMPIC BOULEVARD | LOS ANGELES | CA | 90064 | LOS ANGELES | USA | R43HD052303 | RECOMBINANT ENZYME FUSION PROTEIN FOR LYSOSOMAL STORAGE | 000 | 1 | NIH | 3/23/2006 | $100,000 |
|
